Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 49Prostatic Neoplasms 38Carcinoma, Non-Small-Cell Lung 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms 23Multiple Myeloma 22Lymphoma 21Leukemia, Myeloid, Acute 17Colorectal Neoplasms 17Melanoma 15Lung Neoplasms 13Hodgkin Disease 11Brain Neoplasms 11Medulloblastoma 10Lymphoma, Non-Hodgkin 10Glioblastoma 10Squamous Cell Carcinoma of Head and Neck 9Pancreatic Neoplasms 9Neoplasm Metastasis 9Leukemia, Biphenotypic, Acute 9Leukemia 9Head and Neck Neoplasms 9HIV Infections 9Neuroblastoma 8Hematologic Neoplasms 8Ependymoma 8Glioma 7Carcinoma, Renal Cell 7Astrocytoma 7Wilms Tumor 6

Interventions

temsirolimus 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Advanced Rare Tumours × 1 year × Clear all
NCT01396408 2026-03-27

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Active not recruiting
137 enrolled

Advanced Rare Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡